

Meeting on September 2024 20th-21st

**The new key words in the management of Metabolic Dysfunction Associated
Liver Disease (MASLD): innovation, prevention and multi-disciplinarity**

Endorsed by EASO - EASL - SIO - SIF

First day: 20th September 2024, Aula Morgagni, Policlinico Universitario

Welcome and introduction

Roberto Vettor- Paolo Angeli

(9.00 am-9.15 am)

Innovation

First session (9.15 a.m to 10:35 a.m): Pathophysiology of MASLD (first part)

Chairs: Pietro Maffei, Mario Luca Morieri

- 9.15am-9.35am A Single-cell Atlas of Human Adipose Tissue and Liver (Saverio Cinti, Ancona Italy)
- 9.35am-9.55am Metabolic Flux in Adipose Tissues and Liver in Health and Disease (Amalia Gastaldelli)
- 09.55am-10.15am The Role of Primary Cilium in Adipogenesis and Fibrosis (Bettini Silvia; Milan Gabriella)
- 10.15am-10.35am Genetic and environmental influences on MASLD (Kirsi Pietilainen)
- 10.35am-10.55am Discussion F. Capone, A. di Vincenzo

Coffee break (10.55 am - 11:20 am)

State of the art Lecture (11:25 am- 11:55 am)

Chair: Agatella Barchitta, Maurizio Cesari

- Pathophysiological Relationship between Liver and Heart (Gabriele G. Schiattarella)

Second session (11:55 am 1:35 pm): Pathophysiology of MASLD (second part)

Chairs: Marco Di Pascoli, Marco Rossato

- 11.55 am-12.15pm Adipose Tissue-Liver-Immune System Cross Talk and the development of Metabolic Dysfunction Associated Liver Disease (MASLD)
(Roberto Vettor, Padova)
- 12.15pm-12.35pm Ceramides in Adipose Tissue, Liver and Heart: the link between cardiovascular complications and liver diseases.
(Marina De Bernard, Padova)
- 12.35pm-12.55pm Mitochondrial Bioenergetics calcium handling in Adipose Tissue and Liver
(Rosario Rizzuto, Padova)
- 12.55pm-1.15pm Mechanisms Linking Human Adipose Tissue, Insulin Resistance and Fatty Liver: Insights from Human Genetics
(Hannele Yki-Järvinen)

- 1.15pm-1.35pm Discussion G. Maiolino, C. Piovella

Lunch 1.35 pm-2.30 pm

Prevention

Opening Ceremony

(2.30 pm-3.00 pm)

State of the Art Lecture (3.00 pm-3.30 pm)

Chair: Paolo Angeli; Lorenza Di Pascoli

- The epidemiology and natural history of MASLD: a global perspective

(Patrick Kamath, Mayo Clinic in Rochester, Minnesota)

Third session (3.30 pm – 4.20 pm): Burden and natural history of advanced chronic liver disease

Chairs: Giacomo Germani ; Umberto Cillo

- 3.30pm-3.50pm The burden of advanced chronic liver disease
(Paolo Angeli, Padova, Italy)
- 3.50pm-4.10pm The new vision of decompensation
(Marta Tonon, Padova, Italy)
- 4.10pm-4.30pm ACLF
(Richard Moreau, Paris, France)
- 4.30pm-4.50pm The history of hepatic encephalopathy
(Sara Montagnese, Padova, Italy)
- 4.50pm-5.10pm Discussion: C.G. Gambino e C. Mangini

State of the art Lecture (5.10 pm- 5.40 pm)

Chair: Pere Gines, Liliana Chemello

The change of paradigm in Hepatology: from care to prevention

(Patrizia Burra, Padova)

Fourth session (5.40 p.m – 7.20 p.m): Screening of liver fibrosis

Chairs: Giancarlo Bombonato, Massimo Bolognesi

- 5.40pm - 6pm The impact of innovative technology
(Laurent Castera, Parigi)
- 6pm-6.20pm Screening of liver disease: is it cost effective?
(Miquel Serra Burriel, Zurigo)
- 6.20pm-6.40pm Best screening strategies in the general population
(M.Thiele, Odense, Danimarca)
- 6.40pm-7pm The Liver-screen project
(Pere Gines, Barcellona)
- 7pm-7.20pm Discussion: R. Gagliardi e V. Calvino

Second day: 21st September 2024, Aula Morgagni, Policlinico Universitario
Multi-disciplinarity

State of the art Lecture (9.00 am- 9.30 am)

Chair: Paola Fioretto

- The Exposome Hypothesis in the development of Obesity and MASLD (Gema Fruhbeck Martínez)

Fifth session (9.30 am-10.50 am) round table: From screening to link of care

Chairs: Massimo Annicchiarico, Michele Tessarin

- 9.30am-9.50am The ideal model of care accounting for multidisciplinary:
(Vito di Marco)
- 9.50am-10.30am Responding to stigma and discrimination of patients with liver disease
 - The role of patients and their associations (Marko Korenjak – ELPA)(20 min)
 - The role of EASL (Francesco Paolo Russo, Padova)
- 10.30am-10.50am Viral hepatitis elimination campaign in Europe: where we are?
Liliana Chemello, Padova
- 10.50am-11.10am Discussion: N. Zeni/ A. Accetta

Coffee break (11.10am-11.30 am)

Sixth session (11.30 am – 1.30 pm): Management of metabolic dysfunctions in patients with liver diseases: the present and the future

Chairs: Angelo Avogaro, David Sacerdoti

- 11.30am-11.50am Optimization of the treatment of diabetes in patients with liver disease (Elisabetta Bugianesi, Torino)
- 11.50am-12.10pm Optimization of the treatment of obesity in patients with liver disease (Luca Busetto, Padova)

- 12.10pm-12.30pm The Metabolic microRNA miR-22 as a therapeutic target for the treatment of obesity and MASLD/MASH (Riccardo Panella. Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, DK-2450 Copenhagen SV, Denmark.)
- 12.30pm-12.50pm Resmetiron a potent and selective thyroid hormone receptor beta agonist for the treatment of MASLD/MASH (Vlad Ratziu, Parigi)
- 12.50pm-1.10pm Novo Nordisk Commitment to Liver Diseases (Elcin Darandelli, Denmark)
- 1.10pm-1.30pm Innovation in Obesity Therapy and its Complications (to be defined)
- 1.30PM-1.50PM Discussion: Dassie; R. Fabris

Lunch (1.50 pm-2.50 pm)

State of the art Lecture (2.50 pm- 3.20 pm)

Chair: Roberto Vettor, Paolo Angeli, Volkan Yumuk

The new EASL-EASO guidelines on MASLD **Phil Newsome, Birmingham, UK**

Seventh session (3.20 pm – 5 pm): Prevention of progression to advanced chronic liver disease and its complications

Chairs: Patrizia Pontisso, Antonietta Romano

- 3.20pm-3.40pm News in the management in alcohol related liver disease (Mark Thursz, London)
- 3.40pm-4pm News in the management of viral hepatitis (Pietro Lampertico, Milano)
- 4pm-4.20pm News in the management of cholestatic liver diseases (Ana Lleo de Nalda, Milano)

- 4.20pm-4.40pm Systemic therapy in patients with HCC
(Andrea Casadei Gardini, Milano, San Raffaele)
- 4.40pm-5 pm Infezioni batteriche da MDR e XDR
(Salvatore Piano, Padova)
- 5pm- 5.20pm Discussion: S. Incicco e P. Guerra

State of the art lecture (05.20 pm- 5.50 pm)

Chair: Andrea Martini; Luisa Cavalletto

The thin border between pathophysiological therapy and palliative care in patients with advanced liver disease (Paolo Caraceni, Bologna, Italy)

Meeting Wrap-Up: Outcomes and Future perspectives
Roberto Vettor- Paolo Angeli